logo-loader
viewAlgernon Pharmaceuticals Inc.

Algernon screens patients in Australia for Phase 2 Ifenprodil clinical study aimed at treating a type of lung disease and chronic cough

In animal studies, Ifenprodil showed superiority in reducing fibrosis over two globally approved therapies for a type of lung disease called idiopathic pulmonary fibrosis

Algernon Pharmaceuticals Inc. - Algernon screens patients in Australia for Phase 2 Ifenprodil clinical study aimed at treating a type of lung disease and chronic cough
There are five sites participating in the human study with three located in Australia and two in New Zealand and all five sites have received ethics approval

Algernon Pharmaceuticals Inc (CSE:AGN) (OTCQB:AGNPF) revealed Tuesday that it has begun screening patients for enrolment in a Phase 2 clinical study of its NP-120 drug (Ifenprodil) as a potential treatment for patients with a type of lung disease called idiopathic pulmonary fibrosis (IPF), which results in scarring of the lungs, and chronic cough.

The Vancouver-based clinical-stage pharmaceutical development company said there are five sites participating in the study with three located in Australia and two in New Zealand. All five sites have received ethics approval and have successfully completed their site initiation, the company said.

READ: Algernon Pharmaceuticals prepares to start enrollment for study of Ifenprodil as potential COVID-19 treatment

Algernon has decided to investigate Ifenprodil for both IPF and chronic cough after conducting several animal studies that showed the drug’s superior activity when compared with current standard treatments and a leading Phase 3 drug. The company pointed out that Ifenprodil is a N-methyl-D-aspartate receptor (NDMA) receptor antagonist “specifically targeting the NMDA-type subunit 2B.”

IPF animal study

According to Algernon, Ifenprodil showed superiority in reducing fibrosis over two globally approved therapies for IPF — Roche’s Pirfenidone and Boehringer Ingelheim’s Nintedanib — in a well-established in vivo animal model study.

Data from the study showed a 56% reduction in fibrosis versus untreated controls (p=0.015) in a 21-day bleomycin mouse model, where treatment began on Day 7.

Chronic cough animal study

Algernon also said that Ifenprodil outperformed Merck’s Phase 3 Drug MK-7264 (Gefapixant) in an acute cough study by 110%, in a well-accepted acute cough in-vivo animal study. Pharmidex, a contract research organization (CRO) and a global leader in respiratory research conducted the cough study using the guinea pig citric acid challenge model. Significantly, unlike Merck’s drug Gefapixant, Ifenprodil has “no known taste disturbance,” said the company.

“There has been a significant amount of news flow recently related to our Ifenprodil COVID clinical trial program,” Algernon Pharmaceuticals CEO Christopher J Moreau told investors in a statement.

“However, while this is still an important focus for the company, this is a very appropriate time to remind our shareholders that Ifenprodil was initially selected for advancement into a human clinical trial based on its strong animal data for IPF and chronic cough. These are also important areas with significant unmet clinical needs.”

The company said it would update the market when its first patient has been enrolled.

Shares in Toronto advanced nearly 15% to C$0.27

---Updates for share price---

Contact the author Uttara Choudhury at [email protected]

Follow her on Twitter: @UttaraProactive

Quick facts: Algernon Pharmaceuticals Inc.

Price: 0.315 CAD

CSE:AGN
Market: CSE
Market Cap: $34.67 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Algernon Pharmaceuticals Inc. named herein, including the promotion by the Company of Algernon Pharmaceuticals Inc. in any Content on the Site,...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Algernon Pharmaceuticals studies on Ifenprodil begins with patients on two...

Algernon Pharmaceuticals (CSE: AGN- OTCQB: AGNPF) CEO Christopher Moreau joined Steve Darling from Proactive Vancouver with news the company has started work with patients on two different application for the repurposed drug Ifenprodil. Moreau telling Proactive how the studies will be conducted...

3 days, 15 hours ago

3 min read